Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H20N4O |
Molecular Weight | 308.3776 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1CC[C@@H](CC1)NC2=C3C=CNC3=NC(=N2)C4=CC=CC=C4
InChI
InChIKey=RBZNJGHIKXAKQE-HDJSIYSDSA-N
InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)/t13-,14-
Molecular Formula | C18H20N4O |
Molecular Weight | 308.3776 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19639278Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800016704 | https://www.ncbi.nlm.nih.gov/pubmed/17558436 |
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19639278
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800016704 | https://www.ncbi.nlm.nih.gov/pubmed/17558436 |
Derenofyllin (SLV320) is a selective adenosine A1 receptor antagonist, which is under investigation for the treatment of heart failure with renal dysfunction. Adverse events considered related to SLV320 were dizziness, nausea, transient hypertension and transient hypotension.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17558436 |
9.0 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976 |
15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DERENOFYLLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 2 times / day multiple, intravenous Highest studied dose Dose: 15 mg, 2 times / day Route: intravenous Route: multiple Dose: 15 mg, 2 times / day Sources: Page: p.1016 |
unhealthy, ADULT n = 9 Health Status: unhealthy Condition: heart disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 9 Sources: Page: p.1016 |
|
15 mg single, intravenous Highest studied dose Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: Page: p.527 |
unhealthy, ADULT n = 22 Health Status: unhealthy Condition: heart disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 22 Sources: Page: p.527 |
PubMed
Title | Date | PubMed |
---|---|---|
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. | 2007 Aug |
|
A1 adenosine receptor antagonists, agonists, and allosteric enhancers. | 2009 |
|
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. | 2009 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19919976
1-hour infusion of 5, 10, and 15 mg SLV320
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:11:49 GMT 2023
by
admin
on
Fri Dec 15 17:11:49 GMT 2023
|
Record UNII |
O1Q96UZ63W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
O1Q96UZ63W
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
C96199
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
DTXSID30948047
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
100000175027
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
9208
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL592435
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
251945-92-3
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY | |||
|
DB12446
Created by
admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|